Though recent studies of single agents such as the vascular endothelial growth factor (VEGF) inhibitor bevacizumab have yielded the first molecular therapies deemed “clinically active” in endometrial cancer [2], these studies were performed in patients with advanced or recurrent disease that had progressed after chemotherapy, and response rates were modest. Here, VEGFA is linked to endometrial cancer.